Kevin Joseph Fitzgerald
CSO & EVP, Head of Research; Director · 6 filings · Latest: Apr 7, 2026
ALNYLAM PHARMACEUTICALS, INC.
Ovid Therapeutics Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Mar 5, 2026 | Sale | $323.98 | 658 | $213.2K | 20,569 | |
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Mar 4, 2026 | Sale | $323.08 | 633 | $204.5K | 21,227 | |
ALNY | Fitzgerald Kevin Joseph | — | Mar 5, 2026 | Proposed Sale | $323.69 | 658 | $213.0K | — | |
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Mar 3, 2026 | Sale | $319.73 | 1,652 | $528.2K | 21,860 | |
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Mar 2, 2026 | Sale | $327.65 | 1,598 | $523.6K | 23,512 | |
ALNY | Fitzgerald Kevin Joseph | — | Mar 3, 2026 | Proposed Sale | $321.37 | 1,652 | $530.9K | — | |
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Feb 17, 2026 | Sale | $331.96 | 2,041 | $677.5K | 21,264 | |
ALNY | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Feb 13, 2026 | Sale | $310.08 | 1,959 | $607.4K | 23,305 | |
ALNY | Fitzgerald Kevin Joseph | — | Feb 17, 2026 | Proposed Sale | $331.96 | 2,041 | $677.5K | — | |
ALNY | Fitzgerald Kevin Joseph | — | Jan 13, 2026 | Proposed Sale | $369.10 | 2,290 | $845.2K | — | |
ALNY | Fitzgerald Kevin Joseph | — | Nov 17, 2025 | Proposed Sale | $449.00 | 12,128 | $5.4M | — | |
ALNY | Fitzgerald Kevin Joseph | — | Mar 4, 2025 | Proposed Sale | $241.09 | 844 | $203.5K | — | |
ALNY | Fitzgerald Kevin Joseph | — | Mar 3, 2025 | Proposed Sale | $246.18 | 1,171 | $288.3K | — | |
ALNY | Fitzgerald Kevin Joseph | — | Feb 18, 2025 | Proposed Sale | $256.95 | 1,440 | $370.0K | — | |
ALNY | Fitzgerald Kevin Joseph | — | Nov 27, 2024 | Proposed Sale | $253.98 | 1,531 | $388.8K | — |